Multi-omics Investigation into the Mechanism of Action of an Anti-tubercular Fatty Acid Analogue.

The mechanism of action (MoA) of a clickable fatty acid analogue 8-(2-cyclobuten-1-yl)octanoic acid (DA-CB) has been investigated for the first time. Proteomics, metabolomics, and lipidomics were combined with a network analysis to investigate the MoA of DA-CB against Mycobacterium smegmatis (Msm). The metabolomics results showed that DA-CB has a general MoA related to that of ethionamide (ETH), a mycolic acid inhibitor that targets enoyl-ACP reductase (InhA), but DA-CB likely inhibits a step downstream from InhA. Our combined multi-omics approach showed that DA-CB appears to disrupt the pathway leading to the biosynthesis of mycolic acids, an essential mycobacterial fatty acid for both Msm and Mycobacterium tuberculosis (Mtb). DA-CB decreased keto-meromycolic acid biosynthesis. This intermediate is essential in the formation of mature mycolic acid, which is a key component of the mycobacterial cell wall in a process that is catalyzed by the essential polyketide synthase Pks13 and the associated ligase FadD32. The multi-omics analysis revealed further collateral alterations in bacterial metabolism, including the overproduction of shorter carbon chain hydroxy fatty acids and branched chain fatty acids, alterations in pyrimidine metabolism, and a predominate downregulation of proteins involved in fatty acid biosynthesis. Overall, the results with DA-CB suggest the exploration of this and related compounds as a new class of tuberculosis (TB) therapeutics. Furthermore, the clickable nature of DA-CB may be leveraged to trace the cellular fate of the modified fatty acid or any derived metabolite or biosynthetic intermediate.

[1]  G. Drewes,et al.  The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis , 2022, Science Translational Medicine.

[2]  S. Louie,et al.  Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development , 2022, Metabolites.

[3]  R. Powers,et al.  A reversed phase ultra-high-performance liquid chromatography-data independent mass spectrometry method for the rapid identification of mycobacterial lipids. , 2021, Journal of chromatography. A.

[4]  B. Aldridge,et al.  Identification of cell wall synthesis inhibitors active against Mycobacterium tuberculosis by competitive activity-based protein profiling , 2021, Cell chemical biology.

[5]  R. Powers,et al.  Deciphering the mechanism of action of antitubercular compounds with metabolomics , 2021, Computational and structural biotechnology journal.

[6]  Mingzi M. Zhang,et al.  Chemoproteomic profiling reveals cellular targets of nitro-fatty acids , 2021, bioRxiv.

[7]  C. Lv,et al.  Application of omics- and multi-omics-based techniques for natural product target discovery. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  J. Xia,et al.  MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights , 2021, Nucleic Acids Res..

[9]  L. Alderwick,et al.  Mycobacterium tuberculosis modifies cell wall carbohydrates during biofilm growth with a concomitant reduction in complement activation , 2021, bioRxiv.

[10]  J. Nachega,et al.  Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[11]  M. Kumar,et al.  Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs. , 2021, Life sciences.

[12]  R. Franzini,et al.  Mechanisms and Substituent Effects of Metal-Free Bioorthogonal Reactions. , 2021, Chemical reviews.

[13]  Qiang Li,et al.  The Value of the inhA Mutation Detection in Predicting Ethionamide Resistance Using Melting Curve Technology , 2021, Infection and drug resistance.

[14]  Ralf J M Weber,et al.  struct: an R/Bioconductor-based framework for standardized metabolomics data analysis and beyond , 2020, Bioinform..

[15]  E. Jaramillo,et al.  World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update , 2020, European Respiratory Journal.

[16]  Fiona M. I. Hunter,et al.  Network integration and modelling of dynamic drug responses at multi-omics levels , 2020, Communications Biology.

[17]  L. Guddat,et al.  Structural basis for the broad substrate specificity of two acyl-CoA dehydrogenases FadE5 from mycobacteria , 2020, Proceedings of the National Academy of Sciences.

[18]  G. Cook,et al.  Transcriptional Inhibition of the F1F0-Type ATP Synthase Has Bactericidal Consequences on the Viability of Mycobacteria , 2020, Antimicrobial Agents and Chemotherapy.

[19]  Heebeom Koo,et al.  Biomedical applications of copper-free click chemistry: in vitro, in vivo, and ex vivo , 2019, Chemical science.

[20]  J. Sacchettini,et al.  Genome-wide Phenotypic Profiling Identifies and Categorizes Genes Required for Mycobacterial Low Iron Fitness , 2019, Scientific Reports.

[21]  R. Powers,et al.  Novel Amphiphilic Cyclobutene and Cyclobutane cis-C18 Fatty Acid Derivatives Inhibit Mycobacterium avium subsp. paratuberculosis Growth , 2019, Veterinary sciences.

[22]  Robert Powers,et al.  Combining Mass Spectrometry and NMR Improves Metabolite Detection and Annotation. , 2018, Journal of proteome research.

[23]  Y. Peleg,et al.  Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3 Å resolution , 2018, Nature Communications.

[24]  S. Gibbons,et al.  The Unexpected Essentiality of glnA2 in Mycobacterium smegmatis Is Salvaged by Overexpression of the Global Nitrogen Regulator glnR, but Not by L-, D- or Iso-Glutamine , 2018, Front. Microbiol..

[25]  M. Beckmann,et al.  Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824) , 2018, Scientific Reports.

[26]  Zahoor Ahmad,et al.  Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[27]  L. Kremer,et al.  Identification of inhibitors targeting Mycobacterium tuberculosis cell wall biosynthesis via dynamic combinatorial chemistry. , 2017, Chemical communications.

[28]  B. Evans,et al.  A genetically encoded cyclobutene probe for labelling of live cells. , 2017, Chemical communications.

[29]  R. Zufferey,et al.  Lipidomics and anti-trypanosomatid chemotherapy , 2017, Clinical and Translational Medicine.

[30]  N. Kigozi,et al.  Unsuccessful TB treatment outcomes with a focus on HIV co-infected cases: a cross-sectional retrospective record review in a high-burdened province of South Africa , 2017, BMC Health Services Research.

[31]  R. Miggiano,et al.  Structural investigations on orotate phosphoribosyltransferase from Mycobacterium tuberculosis, a key enzyme of the de novo pyrimidine biosynthesis , 2017, Scientific Reports.

[32]  Thomas R. Ioerger,et al.  Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis , 2017, mBio.

[33]  Ali Ebrahim,et al.  Multi-omic data integration enables discovery of hidden biological regularities , 2016, Nature Communications.

[34]  G. Minasov,et al.  Structure of the Essential Mtb FadD32 Enzyme: A Promising Drug Target for Treating Tuberculosis. , 2016, ACS infectious diseases.

[35]  D. Wishart.  Emerging applications of metabolomics in drug discovery and precision medicine , 2016, Nature Reviews Drug Discovery.

[36]  L. Bi,et al.  Crystal structure of FadD32, an enzyme essential for mycolic acid biosynthesis in mycobacteria , 2015, Scientific Reports.

[37]  G. Besra,et al.  Mycolic acids: deciphering and targeting the Achilles' heel of the tubercle bacillus , 2015, Molecular microbiology.

[38]  J. Swinnen,et al.  Lipidomics in drug development. , 2015, Drug discovery today. Technologies.

[39]  Joshua D. Rabinowitz,et al.  The return of metabolism: biochemistry and physiology of the pentose phosphate pathway , 2014, Biological reviews of the Cambridge Philosophical Society.

[40]  R. Powers,et al.  Development of Cyclobutene‐ and Cyclobutane‐Functionalized Fatty Acids with Inhibitory Activity against Mycobacterium tuberculosis , 2014, ChemMedChem.

[41]  P. Lu,et al.  ATP synthase in mycobacteria: special features and implications for a function as drug target. , 2014, Biochimica et biophysica acta.

[42]  M. Daffé,et al.  Mycolic acids: structures, biosynthesis, and beyond. , 2014, Chemistry & biology.

[43]  Xi-jun Wang,et al.  Metabolomics and Proteomics Annotate Therapeutic Properties of Geniposide: Targeting and Regulating Multiple Perturbed Pathways , 2013, PloS one.

[44]  C. Slugovc,et al.  Inverse electron demand Diels-Alder (iEDDA)-initiated conjugation: a (high) potential click chemistry scheme. , 2013, Chemical Society reviews.

[45]  David G. Russell,et al.  Intracellular Mycobacterium tuberculosis Exploits Host-derived Fatty Acids to Limit Metabolic Stress* , 2013, The Journal of Biological Chemistry.

[46]  N. Vale,et al.  Metabolism of the antituberculosis drug ethionamide. , 2012, Current drug metabolism.

[47]  C. Nikam,et al.  Can inhA mutation predict ethionamide resistance? , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[48]  H. Maamar,et al.  Wax Ester Synthesis is Required for Mycobacterium tuberculosis to Enter In Vitro Dormancy , 2012, PloS one.

[49]  R. Bhattacharyya,et al.  Isoniazid and thioacetazone may exhibit antitubercular activity by binding directly with the active site of mycolic acid cyclopropane synthase: Hypothesis based on computational analysis , 2012, Bioinformation.

[50]  R. Powers,et al.  Predicting the in vivo mechanism of action for drug leads using NMR metabolomics. , 2012, ACS chemical biology.

[51]  Richard D. LeDuc,et al.  Mapping Intact Protein Isoforms in Discovery Mode Using Top Down Proteomics , 2011, Nature.

[52]  G. Besra,et al.  Mycobacterium tuberculosis acyl carrier protein synthase adopts two different pH-dependent structural conformations. , 2011, Acta crystallographica. Section D, Biological crystallography.

[53]  J. Palomino,et al.  Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. , 2011, The Journal of antimicrobial chemotherapy.

[54]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[55]  Alimuddin Zumla,et al.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. , 2010, The Lancet. Infectious diseases.

[56]  W. Rom,et al.  New drugs and regimens for treatment of TB , 2010, Expert review of anti-infective therapy.

[57]  J. Bayona,et al.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis , 2010, The Lancet.

[58]  Zhiguo He,et al.  Cell wall proteome analysis of Mycobacterium smegmatis strain MC2 155 , 2010, BMC Microbiology.

[59]  R. Powers.  NMR metabolomics and drug discovery , 2009, Magnetic resonance in chemistry : MRC.

[60]  O. Burlet-Schiltz,et al.  The Pks13/FadD32 Crosstalk for the Biosynthesis of Mycolic Acids in Mycobacterium tuberculosis* , 2009, The Journal of Biological Chemistry.

[61]  R. Powers,et al.  Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: role of D-alanine racemase. , 2007, Journal of proteome research.

[62]  S. Jackowski,et al.  Biosynthesis of Pantothenic Acid and Coenzyme A , 2007, EcoSal Plus.

[63]  G. Besra,et al.  The Mycobacterium tuberculosis FAS‐II condensing enzymes: their role in mycolic acid biosynthesis, acid‐fastness, pathogenesis and in future drug development , 2007, Molecular microbiology.

[64]  G. Bai,et al.  Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.

[65]  James C Sacchettini,et al.  Dual inhibition of mycobacterial fatty acid biosynthesis and degradation by 2-alkynoic acids. , 2006, Chemistry & biology.

[66]  G. Besra,et al.  Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis , 2005, Clinical Microbiology Reviews.

[67]  L. P. Ormerod.  Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. , 2005, British medical bulletin.

[68]  G. Besra,et al.  Acyl-CoA Carboxylases (accD2 and accD3), Together with a Unique Polyketide Synthase (Cg-pks), Are Key to Mycolic Acid Biosynthesis in Corynebacterianeae Such as Corynebacterium glutamicum and Mycobacterium tuberculosis* , 2004, Journal of Biological Chemistry.

[69]  I. Smith,et al.  Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence , 2003, Clinical Microbiology Reviews.

[70]  Gurdyal S Besra,et al.  The methyl-branched fortifications of Mycobacterium tuberculosis. , 2002, Chemistry & biology.

[71]  X. Liu,et al.  Identification of a secreted superoxide dismutase in Mycobacterium avium ssp. paratuberculosis. , 2001, FEMS microbiology letters.

[72]  A. Quémard,et al.  Mycolic acid synthesis: a target for ethionamide in mycobacteria? , 1992, Antimicrobial Agents and Chemotherapy.

[73]  A. Quémard,et al.  Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum , 1991, Antimicrobial Agents and Chemotherapy.

[74]  F. Winder,et al.  Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. , 1971, Journal of general microbiology.

[75]  R. Dubos.  THE EFFECT OF LIPIDS AND SERUM ALBUMIN ON BACTERIAL GROWTH , 1946, The Journal of experimental medicine.